TB Fragment

TB Fragment denotes the short, actin-binding fragment of Thymosin Beta-4 (Tβ4): the N-terminally acetylated heptapeptide Ac-LKKTETQ, corresponding to residues 17-23 of the 43-residue parent peptide. The hexapeptide core LKKTET (residues 17-22) is strongly conserved across the β-thymosin family and other actin-binding proteins and is the segment most often described as the central actin-binding motif. This material is the SHORT active fragment and is chemically distinct from full-length Tβ4: the synthetic Ac-LKKTETQ heptapeptide carries the molecular formula C38H68N10O14 (CAS 885340-08-9; PubChem CID 62707662), whereas full-length Tβ4 is a 43-residue acetylated peptide of roughly 5 kDa (CAS 77591-33-4). Analytical work synthesized and characterized this heptapeptide directly by HPLC and high-resolution mass spectrometry (Esposito et al., 2012) and by LC-MS (Ho et al., 2012), confirming the identity of the marketed fragment as Ac-LKKTETQ. Because the literature regards the fragment and the full-length peptide as separate species, the sections below attribute each report to the molecule actually examined.

The molecular role most directly tied to the fragment is the binding and sequestration of monomeric G-actin. Foundational biochemistry established full-length Tβ4 as the major intracellular actin-sequestering peptide forming a 1:1 complex with actin monomers (Safer et al., 1991; Weber et al., 1992). Fragment-focused work then examined the isolated motif: Hannappel & Wartenberg (1993) compared the actin-sequestering ability of Tβ4, of Tβ4 fragments, and of Tβ4-like peptides using the DNase I inhibition assay, providing a direct read on the motif's contribution to actin binding. This biochemistry frames the LKKTET(Q) sequence as the central actin-contact region examined for the fragment.

Structural and mutational studies have mapped how the 17-23 segment engages actin. Mutational analysis of full-length variants resolved the N-terminal helix (residues 1-16) and the hexapeptide motif (residues 17-22) as separate structural entities, with charged and hydrophobic residues participating in the actin interaction (Van Troys et al., 1996). NMR work in solution examined the conformational requirements of Tβ4 mutants and correlated them with actin binding (Simenel et al., 2000). Crystallographic and NMR studies of the β-thymosin / WH2 module then positioned the central LKKTET segment between actin subdomains: Irobi et al. (2004), working with a gelsolin-Tβ4 hybrid, and Hertzog et al. (2004) described the actin-assembly switch, Didry et al. (2012) used X-ray, SAXS, and NMR to examine how individual residues distinguish sequestering from assembly-promoting behavior, and Xue et al. (2014) resolved Tβ4:actin complexes relevant to the profilin-exchange step. Together these reports characterize the structural context of the actin-binding motif carried by the fragment.

A distinct strand of research has examined the actin-binding region in angiogenesis and cell-migration model systems rather than the whole peptide. Philp et al. (2003) examined the actin-binding site of Tβ4 in angiogenesis assays, associating the short actin-binding motif with angiogenic endpoints. Dettin et al. (2011) designed synthetic peptides corresponding to the N-terminus, the central part, and the C-terminus of Tβ4 and examined their behavior in in vitro and in vivo angiogenesis model systems. Wyczółkowska et al. (2007) examined Tβ4 and Tβ4-derived peptides — including the 17-23 fragment — in mast-cell exocytosis assays, noting the LKKTET motif as the implicated segment. These reports characterize cell-migration and angiogenesis pathways in model systems rather than human outcomes.

Review literature on the β-thymosin family situates the fragment within the broader actin-regulation field. Reviews describe Tβ4 as the principal G-actin-sequestering peptide and survey the β-thymosin / WH2 module, the conservation of the LKKTET motif, and the intracellular and extracellular activities of the family (Mannherz & Hannappel, 2009; Hannappel, 2007; Goldstein et al., 2005; Goldstein et al., 2012). These syntheses make clear that the bulk of in vivo and clinical investigation has used the full-length peptide, while the short fragment is studied chiefly in actin biochemistry, structural biology, and cell-based angiogenesis and migration assays. Observations on the full-length peptide are not assumed to transfer to the fragment, and the two are catalogued under separate molecular identifiers.